CELU vs ILMN vs FATE vs BRKR vs BEAM

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Illumina, Inc. (ILMN) offers the better valuation at 26. 0x trailing P/E (27. 2x forward), making it the more compelling value choice. Analysts rate Illumina, Inc. (ILMN) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bruker Corporation is actually cheaper at 20.

8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Bruker Corporation (BRKR) delivered a total return of -34.

1%, compared to -99. 1% for Celularity Inc. (CELU). Over 10 years, the gap is even starker: BEAM returned +72. 4% versus CELU's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 20β versus Beam Therapeutics Inc. 's 2. 08β — meaning BEAM is approximately 73% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -22. 2% for FATE. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bruker Corporation (BRKR) trades at 20.

8x forward P/E versus 27. 2x for Illumina, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1552. 7% to $39. 50.

In this comparison, CELU (26.

2% yield), BRKR (0. 3% yield) pay a dividend. ILMN, FATE, BEAM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Celularity Inc.

(CELU) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (26. 2% yield). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CELU: -99. 1%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CELU is a small-cap income-oriented stock; ILMN is a mid-cap quality compounder stock; FATE is a small-cap quality compounder stock; BRKR is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock. CELU pays a dividend while ILMN, FATE, BRKR, BEAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.